Pimicotinib Significantly Improved Outcomes For Patients With Tenosynovial Giant Cell Tumor In A Global Phase III Trial

(MENAFN - PR Newswire) – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p< 0.0001 ) –– ...Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute